Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 May-Jun;91(Supplementary 1):S87-S89.
doi: 10.25259/IJDVL_216_2024.

Erythrodermic atopic dermatitis responding to tralokinumab after dupilumab failure

Aida Lara-Moya  1 , Vicente Exposito-Serrano  1 , Patricia Garbayo-Salmons  1 , Mireia Sabat Santandreu  1
Affiliations
Free article

Erythrodermic atopic dermatitis responding to tralokinumab after dupilumab failure

Aida Lara-Moya et al. Indian J Dermatol Venereol Leprol. 2025 May-Jun.
Free article
No abstract available

PubMed Disclaimer

References

    1. GirolomoniG,de Bruin-WellerM,AokiV,KabashimaK,DeleuranM,PuigL,.Nomenclature and clinical phenotypes of atopic dermatitis.Ther Adv Chronic Dis.2021; 12:20406223211002979
    1. WeidingerS,NovakN,.Atopic dermatitis.Lancet.2016; 387:1109-22
    1. WollenbergA,BlauveltA,Guttman-YasskyE,WormM,LyndeC,LacourJP,.Tralokinumab for moderate-to-severe atopic dermatitis: Results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2).Br J Dermatol.2021; 184:437-49
    1. SilverbergJI,TothD,BieberT,AlexisAF,ElewskiBE,PinkAE,.Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: Results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial.Br J Dermatol.2021; 184:450-63
    1. De GreefA,GhislainPD,BulinckxA,CosterA,de HalleuxC,DamsinT,.Real-life experience of tralokinumab for the treatment of adult patients with severe atopic dermatitis: A multicentric prospective study.Clin Drug Investig.2023; 43:299-306

LinkOut - more resources